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Abstract
We identified a PSEN1 mutation carrier from the world’s largest autosomal dominant Alzheimer’s 
disease kindred who did not develop mild cognitive impairment until her seventies, three decades 
after the expected age of clinical onset. She had two copies of the APOE3 Christchurch (R136S) 
mutation, unusually high brain amyloid, and limited tau/tangle and neurodegenerative 
measurements. Our findings have implications for APOE’s role in the pathogenesis, treatment, and 
prevention of Alzheimer’s disease.
Arboleda-Velasquez et al. Page 2
Nat Med. Author manuscript; available in PMC 2020 May 04.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Alzheimer’s disease (AD)-causing mutation carriers who remain cognitively unimpaired 
until older ages could help in the discovery of risk-reducing genes. We have identified about 
1,200 Colombian Presenilin 1 (PSEN1) E280A mutation carriers from the world’s largest 
known autosomal dominant Alzheimer’s disease (ADAD) kindred1. While there is some 
variability in the age at clinical onset and disease course, as reported for other ADAD 
pedigrees,2–5 the kindred’s carriers develop mild cognitive impairment (MCI) and dementia 
at the respective median ages of 44 (95% CI, 43–45) and 49 (95% CI, 49–50) years6. One 
mutation carrier did not develop MCI until her seventies, nearly three decades after the 
typical age of onset. Here, we describe her clinical and biomarker findings, identify a 
potentially protective gene variant, and consider implications for the understanding, 
treatment and prevention of AD.
The subject’s pedigree is shown in Extended Data 1. Exact age and other identifying 
information are omitted to protect her anonymity. She was confirmed to have the amyloid-
β42 (Aβ42)-overproducing PSEN1 E280A mutation, described by family informants to be 
cognitively unimpaired until her seventies, and subsequently met criteria for MCI. Her 
memory deficits were limited to recent events and her neurological exams were normal. The 
Supplementary Table 1 shows relative stability in cognitive performance during a 24-month 
assessment period. Due to our partial reliance on informant reports, it is not possible to 
confirm whether her resistance to AD dementia is due to delayed MCI onset, prolonged MCI 
duration, or a combination of both.
Whole exome sequencing corroborated her PSEN1 E280A mutation and discovered that she 
had two copies of the rare Christchurch (APOEch)7 mutation (an arginine-to-serine 
substitution at amino acid 136, corresponding to codon 154) in APOE3. Sanger DNA 
sequencing confirmed the latter finding (Extended Data 2). Whole genome sequencing and a 
Genomizer8 analysis were used to comprehensibly identify and rank all potentially 
significant rare and common variants, confirm the PSEN1 E280A mutation as her primary 
risk factor, and identify APOE3ch homozygosity as her most likely genetic modifier. Single 
cell RNA sequencing of peripheral blood mononuclear cells confirmed allele-specific 
expression of her PSEN1 E280A mutation (Supplementary Table 2 & Supplementary Table 
3). We were unable to identify any additional homozygote carriers of the ApoE3ch that also 
carry the PSEN1 E280A variant. In a post hoc analysis of 117 kindred members,9 6% had 
one copy of this otherwise rare APOE3ch mutation (all closely related individuals), 
including four PSEN1 E280A mutation carriers who progressed to MCI at the mean age of 
45. We thus postulate that APOE3ch homozygosity is required to postpone the clinical onset 
of ADAD.
APOE, the major susceptibility gene for late-onset AD, has three common alleles (APOE2, 
3, and 4). Compared to the most common APOE3/3 genotype, which is considered neutral 
with regard to AD risk, APOE2 is associated with a lower AD risk and older age at dementia 
onset, and each additional copy of APOE4 is associated with a higher risk and younger age 
at onset.10 Carriers of APOEch and other rare mutations in APOE’s low density lipoprotein 
receptor (LDLR) binding region commonly have hyperlipoproteinemia type III (HLP-III), 
similar to that observed in 5–10% of APOE2 homozygotes11. The subject had a history of 
dyslipidemia treated with atorvastatin 40 mgs per day. While not previously diagnosed, the 
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participant was confirmed to have HLP-III, including APOEch and elevated triglyceride and 
total cholesterol levels (Supplementary Table 4). Upon diagnosis, the atorvastatin dose was 
raised to 80 mgs per day and ezetimibe 10 mgs per day was prescribed.
Neuroimaging measurements were used to clarify whether the participant’s resistance to 
clinical onset of AD was associated with relatively little fibrillar Aβ plaque burden despite 
more than seventy years of Aβ42 overproduction or with relatively high Aβ plaque burden 
but limited downstream measurements of paired helical filament (PHF) tau (neurofibrillary 
tangle burden) and neurodegeneration. The participant’s neuroimaging findings are shown in 
Figure 1. She had unusually high positron emission tomography (PET) measurements of Aβ 
plaque burden, as indicated by a higher mean cortical-to-cerebellar Pittsburgh Compound B 
(PiB) distribution volume ratio (DVR=1.96) than in PSEN1 E280A carriers who developed 
MCI in their forties (DVRs 1.49–1.60). Despite her high Aβ plaque burden, the magnitude 
and/or spatial extent of her PHF tau burden and neurodegeneration were relatively limited, 
particularly for her older age: Her flortaucipir (tau) PET measurements were restricted to 
medial temporal and occipital regions with relative sparing of other regions that are 
characteristically affected in the clinical stages of AD (Figure 1a).
The subject’s fluorodeoxyglucose PET measurements of the cerebral metabolic rate for 
glucose (CMRgl, Figure 1b) were preserved in brain regions that are known to be 
preferentially affected by AD, including higher precuneus-to-whole brain glucose 
metabolism than PSEN1 E280A mutation carriers who developed MCI at younger ages. Her 
MRI-based hippocampal-to-whole brain volume, an atrophy measurement that can be 
affected by AD and/or normal aging, was within the range of mutation carriers who 
developed MCI in their forties (Figure 1c). She also had relatively low plasma neurofilament 
light chain (NfL) measurements (20.24 pg/mL), a blood marker of axonal injury and 
neurodegeneration12 related to familial AD, particularly for her older age (her result and the 
mean and standard deviation of non-mutation carriers in the same age range, data not 
shown). Our findings suggest that this APOE3ch homozygote’s resistance to the clinical 
onset of AD is mediated through a mechanism that limits tau pathology and 
neurodegeneration even in the face of high Aβ plaque burden.
To study the APOE3ch variant’s functional consequences, we compared Aβ42 aggregation in 
vitro in the presence of human recombinant ApoE3 protein, presence of ApoE3ch protein, 
and absence of ApoE. Aβ42 aggregation was highest in the presence of human ApoE3 
protein (C-terminus domain), lower in the presence of human ApoE3ch (similar to that 
observed in the presence of ApoE213), and lowest in the absence of any ApoE (Extended 
Data 3). This finding was confirmed using a split-luciferase complementation assay sensitive 
to the characterization of potentially neurotoxic Aβ42 oligomers13. These in vitro results 
showing lower ability of the ApoE3ch to trigger Aβ42 aggregation suggest that the subject 
may have had even greater Aβ plaque deposition had she survived to her seventies without 
the APOE3ch/3ch genotype.
The R136S mutation is located in a region of APOE known to play a role in binding to 
lipoprotein receptors and heparan sulfate proteoglycans (HSPG)11. Previous reports showed 
that compared to ApoE3, ApoE2 and ApoE3ch are associate with a 98% and 60% reductions 
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in LDLR binding, respectively11,14. HSPG has been suggested to promote Aβ aggregation 
and neuronal uptake of extracellular tau; and ApoE-binding may be necessary for some of 
these effects15,16. Our analyses of heparin binding showed that ApoE4 had higher affinity 
for heparin compared to ApoE3 and ApoE217. We also found that compared to other ApoE 
isoforms, ApoE3ch displayed the lowest heparin binding ability (Figure 2). We then raised a 
monoclonal antibody (1343A) against ApoE amino acids 130–143 (including R136S) and 
demonstrated its ability to reduce wild type ApoE3 heparin binding to that associated with 
the ApoE3ch protein in vitro (Figure 2). These studies suggest that antibodies or other 
molecules binding to this ApoE region or modulating ApoE-HSPG interactions could 
reproduce this potentially protective effect of ApoE3ch.
We describe a homozygous APOE3ch subject remarkably resistant to the clinical onset of 
ADAD dementia. Our data support a model in which APOE variants differ in the extent of 
their pathogenic functions (APOE3ch and APOE2<3<4) and APOE3ch and APOE2 are 
associated with greatest functional loss. We postulate that APOE3ch exerts beneficial effects 
on downstream tau pathology and neurodegeneration, even in the face of high Aβ plaque 
burden, and that the beneficial effect is related, in part, to altered affinity for HSPG or other 
ApoE receptors. While this mutation may not be deterministic, our data strongly suggest that 
APOE3ch is not neutral to the AD phenotype as it would be expected for the wild type 
APOE3. APOE3ch is the best candidate that we can clearly identify as a genetic modifier in 
this subject and fully recognize that other factors could have played a role to achieve such 
strong resistance phenotype. We postulate that interventions that safely and sufficiently edit 
APOE, lower its expression, or modulate its pathogenic functions related to HSPG 
interactions could have a profound impact on the treatment and prevention of AD.
Methods
Clinical assessments
Institutional review boards from the University of Antioquia, Massachusetts General 
Hospital, and the Schepens Eye Research Institute of Massachusetts Eye and Ear approved 
this study. Like all of the research participants, the proband case provided her informed 
consent. Clinical ratings and neuropsychological tests were performed as noted in 
Supplementary Table 1.
All clinical measures were undertaken at the University of Antioquia (Medellín, Colombia) 
and were conducted in Spanish by physicians and psychologists trained in assessment. 
Neurocognitive testing included the Mini-Mental State Examination (MMSE), the Clinical 
Dementia Rating (CDR), and a Spanish version of the Consortium to Establish a Registry 
for Alzheimer’s disease battery, which have been adapted to this Colombian population18. 
Additional testing consisted of the Yesavage Geriatric Depression Scale and the Functional 
Assessment Staging test, which were done before imaging.
Additional studies were conducted after the PSEN1 E280A mutation carrier was discovered 
to have two copies of the APOE3ch variant. A fasting serum lipid panel was performed to 
explore the possibility of hyperliproteinemia type III (Supplementary table 4), a condition 
found in 5–10% of persons homozygous for the relatively AD protective APOE2 allele and 
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in most but not all APOE3ch carriers19. Further information can be found in the Life 
Sciences Reporting Summary.
Whole exome sequencing
Whole-exome capture and sequencing were performed using Illumina chemistry for variant 
discovery; rare variants with less than 1% frequency in genes previously associated with AD 
were considered in the search for candidate risk modifiers. Specifically, we identified rare 
DNA variants (minor allele frequency <1%) within exonic regions and splice-site junctions 
(5 bp into introns) of genes using bioinformatics tools. We constructed and sequenced whole 
exome libraries on an Illumina HiSeq 4000 sequencer with the use of 151 bp paired-end 
reads. Library construction was performed using a previously described protocol20 modified 
as follows. Genomic DNA input was reduced from 3 μg to 50 ng in 10 μL of solution and 
enzymatically sheared. Dual-indexed Illumina paired end adapters were replaced with 
palindromic forked adapters with unique 8 base index sequences embedded within the 
adapter and added to each end for adapter ligation. We performed in-solution hybrid 
selection using the Illumina Rapid Capture Exome enrichment kit with 38Mb target territory 
(29Mb baited). The targeted region included 98.3% of the intervals in the Refseq exome 
database. Dual-indexed libraries were pooled into groups of up to 96 samples prior to 
hybridization. The enriched library pools were quantified via PicoGreen after elution from 
streptavadin beads and then normalized. For cluster amplification and sequencing, the 
libraries prepared using forked, indexed adapters were quantified using quantitative PCR 
(KAPA biosystems), normalized to 2 nM using Hamilton Starlet Liquid Handling system, 
and pooled with equal volume using the Hamilton Starlet Liquid Handling system. Pools 
were then denatured in 0.1 N NaOH. Denatured samples were diluted into strip tubes using 
the Hamilton Starlet Liquid Handling system. Cluster amplification of the templates was 
performed according to the manufacturer’s protocol (Illumina) using the Illumina cBot. 
Flowcells were sequenced on HiSeq 4000 Sequencing-by-Synthesis Kits, then analyzed 
using RTA2.7.3
Exome sequencing data was processed and analyzed with the bioinformatics pipeline of the 
Center’s Clinical Exome Sequencing of the Center for Personalized Medicine (CPM) 
Clinical Genomics Laboratory and the Translational Genomics Research Institute. Briefly, 
we used Edico Genome’s Dragen Genome Pipeline with default parameters to perform 
sequence alignment and variant calling. We used the open source software samtools and 
bcftools (https://samtools.github.io/) along with a set of custom scripts to perform coverage 
determination and initial variant filtering based on ExAC (Exome Aggregation Consortium, 
http://exac.broadinstitute.org/) allele frequencies. Sequence alignment was done against the 
Human hs37d5 decoy genome. To identify the potential modifier variants, a primary gene 
list of 15 genes was generated based on two HPO terms: HP:0002511, Alzheimer disease; 
HP:0003584, Late onset. These genes were AAGAB, ABCC8, AKT2, APOE, APP, BEAN1, 
GATA1, GCK, HMGA1, HNF1B, HNF4A, LDB3, PAX4, PSEN1, and PSEN2. Rare DNA 
variants (minor allele frequency <1%) within exonic regions and splice-site junctions (5 bp 
into introns) of these genes were further annotated and analyzed using a commercial tool 
(Cartagenia v5.0). Sequence alterations were reported according to the Human Genome 
Variation Society (HGVS v2.0) nomenclature guidelines. The subject did not have other 
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mutations in PSEN1, amyloid precursor protein (APP), tau genes or in the chemokine gene 
cluster suggested to be associated with an older onset age in this kindred19. Further 
information can be found in the Life Sciences Reporting Summary.
Whole genome sequencing
Whole-genome sequencing (WGS) and a Genomizer analysis (v 10.1.0) were used to 
conduct a comprehensive and unbiased ranking of other potential genetic risk modifiers, 
including those associated with a lower risk of Alzheimer’s dementia, helping to exclude 
other potentially protective genetic factors10. For processing the WGS data, the same dragen 
pipeline described above was used. The data was aligned to the GRCh37 decoy genome 
(hs37d5). Variants that were called at a depth of <10X were filtered out and then were 
annotated using Ensembl’s Variant Effect Predictor (VEP) tool. The version of VEP using 
was v93. The filtered and annotated set of variants was then compiled for Genomizer 
analysis. Further information can be found in the Life Sciences Reporting Summary.
APOE Genotyping by Sanger sequencing
Reaction mixture for the amplification process was performed in a 50 μL volume that 
included the following components: 1xPfuUltra II Hostart Master Mix, 1μL of each primer 
(10 μmol/L)(Forward primer: 5’- AGCCCTTCTCCCCGCCTCCCACTGT-3’ and Reverse 
primer: 5’- CTCC GCCACCTGCTCCTTCACCTCG-3’), 5% DMSO and 1μL of genomic 
DNA (100 ng/μL)21. PCR cycling was run with initial denaturation at 95°C for 2 min 
followed by 35 cycles with denaturation at 95°C for 20 seconds, annealing at 60°C for 30 
seconds, extension at 72°C for 40 seconds, and a final extension at 72°C for 5 minutes. PCR 
products were purified using QIAquick Gel Extraction kit from Qiagen and sequenced by 
MGH CCIB DNA core using the 3730xl sequencer from Applied Biosystems. To avoid 
errors in sampling the blood sample used for Sanger sequencing was different from the 
sample used for the WGS analysis. Genotyping of four descendants of the case were 
confirmed to be heterozygote carriers of the ApoE3ch as expected when one parent is 
homozygote (Extended data 2). Data is representative of n = 2 independent experiments and 
further validated independently with whole exome and whole genome sequencing. Further 
information can be found in the Life Sciences Reporting Summary.
MRI and PET imaging
Pittsburgh Compound B (PiB), flortaucipir (FTP) positron emission tomography (PET) and 
structural magnetic resonance imaging (MRI) measurements were acquired at Massachusetts 
General Hospital and analyzed at Massachusetts General Hospital and Banner Alzheimer’s 
Institute as previously described2. Fluorodeoxyglucose PET images were acquired at the 
University of Antioquia, Colombia, and analyzed as previously described22. Imaging data 
from the case were compared to those from younger PSEN1 E280A mutation carriers who 
developed MCI at the kindred’s expected age at clinical onset, and from mutation carriers 
who were cognitively unimpaired.
Magnetic resonance imaging (MRI) was performed on a 3 Tesla Tim Trio (Siemens) and 
included a magnetization-prepared rapid gradient-echo (MPRAGE) processed with 
Freesurfer (FS) to identify grey white and pial surfaces to permit regions of interest (ROI) 
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parcellation as follows: cerebellar grey, hippocampus, and the following Braak Stage related 
cortices: entorhinal, parahippocampal, inferior temporal, fusiform, posterior cingulate, as 
described previously23–26.
18F-Flortaucipir (FTP) for positron emission tomography (PET) was prepared at MGH with 
a radiochemical yield of 14±3% and specific activity of 216±60 GBq/μmol at the end of 
synthesis (60 min), and validated for human use27. 18F-FTP PET was acquired from 80–100 
minutes after a 9.0 to 11.0 mCi bolus injection in 4 × 5-minute frames. 11C-Pittsburgh 
Compound B (11C PiB) PET images were prepared and images acquired as previously 
described23 using a Siemens/CTI (Knoxville, TN) ECAT HR+ scanner (3D mode; 63 image 
planes; 15.2cm axial field of view; 5.6mm transaxial resolution and 2.4mm slice interval. 
11C PiB PET was acquired with a 8.5 to 15 mCi bolus injection followed immediately by a 
60-minute dynamic acquisition in 69 frames (12×15 seconds, 57×60 seconds). PET images 
were reconstructed and attenuation-corrected, and each frame was evaluated to verify 
adequate count statistics and absence of head motion.
18F FTP specific binding was expressed in FS ROIs as the standardized uptake value ratio 
(SUVR) to cerebellum, similar to a previous report26, using the FS cerebellar grey ROI as 
reference. For voxelwise analyses, each subject’s MPRAGE was registered to the template 
MR in SPM8 (SPM), and the spatially transformed SUVR PET data was smoothed with a 8 
mm Gaussian kernel to account for individual anatomic differences28. To account for 
possible 18F FTP off-target binding in choroid plexus, which may confound hippocampal 
signal, we used a linear regression to regress the choroid plexus, as previously reported29.
11C PiB PET data were expressed as the distribution volume ratio (DVR) with cerebellar 
grey as reference tissue; regional time-activity curves were used to compute regional DVRs 
for each ROI using the Logan graphical method applied to data from 40 to 60 minutes after 
injection23,30. 11C PiB retention was assessed using a large cortical ROI aggregate that 
included frontal, lateral temporal and retrosplenial cortices (FLR) as described 
previously31,32.
18F-fludeoxyglucose PET was performed on a 64-section PET/computed tomography 
imaging system (Biograph mCT; Siemens) using intravenous administration of 5 mCi (185 
million Bq) of 18F-fludeoxyglucose after a 30-minute radiotracer uptake period when resting 
in a darkened room, followed by a 30-minute dynamic emission scan (six 5-minute frames). 
Images were reconstructed with computed tomographic attenuation correction.
Precuneus to whole-brain cerebral metabolic rate for glucose (CMRgl) ratios were 
characterized from a bilateral region of interest (ROI) in each participant’s 18F-
fludeoxyglucose PET image using an automated brain mapping algorithm (SPM8; http://
www.fil.ion.ucl.ac.uk/spm/software/spm8). Hippocampal to total intracranial volume ratios 
were characterized from bilateral ROIs in each participant’s T1-weighted MR image using 
FreeSurfer (http://surfer.nmr.mgh.harvard.edu). All images were visually inspected to verify 
ROI characterization. Further information can be found in the Life Sciences Reporting 
Summary.
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Plasma NfL assay
For NfL analysis, plasma was shipped on dry ice to the Clinical Neurochemistry Laboratory 
at Sahlgrenska University Hospital, Mölndal, Sweden. NfL concentration was measured 
using an in house Single molecule array (Simoa) assay, as previously described in detail33. 
The measurements were performed by board-certified laboratory technicians who were 
masked to clinical and genetic data. For a quality control (QC) sample with a concentration 
11.7 pg/mL, repeatability was 8.02% and intermediate precision was 20.2%. For a QC 
sample with a concentration 182 pg/mL, repeatability was 5.74% and intermediate precision 
was 8.34%.
Amyloid aggregation studies
Recombinant human ApoE3 protein fragments (including the carboxyl-terminus domain 
plus a histidine tag; 
MLGQSTEELRVRLASHLRKLRKRLLRDADDLQKRLAVYQAGAREGAERGLSAIRER
LGPLVEQGRVRAATVGSLAGQPLQERAQAWGERLRARMEEMGSRTRDRLDEVKEQ
VAEVRAKLEEQAQQIRLQAEAFQARLKSWFELPVEDMQRQWAGLVEKVQAAVGTS
AAPVPSDNHHHHHH) with and without the Christchurch mutation were produced in 
bacteria, purified (Innovagen), and used to assess the differential effects of these proteins on 
Aβ42 aggregation in vitro using Thioflavin T (SensoLyte® ThT β-Amyloid (1–42) 
Aggregation kit, cat. # AS-72214). 55 μM of Aβ42 was added to solutions of either 10μM 
wild type ApoE3 or ApoEch (136Arg→Ser) proteins in a transparent, no-binding 96-well 
plate. Samples were then mixed with 2 mM Thioflavin T dye and fluorescence was read at 
Ex/Em = 440/484 nm at intermittent time intervals over 2 hours. The plate was kept at 37°C 
with 15 seconds shaking between reads.
Full-length ApoE3 proteins with and without the Christchurch mutation were also expressed 
in Flp-In™ T-REx™ 293 (Thermo Fisher Scientific) mammalian cells via transient 
transfection to confirm the impact of these proteins on Aβ42 aggregation using a previously 
published split-luciferase complementation assay34 and based on the known toxicity of the 
oligomeric intermediates of Aβ35. The latter analysis was conducted using the human 
APOE3 expression from Addgene (Plasmid #8708636) as the WT or APOE3 with the 
Christchurch variant introduced via site-directed mutagenesis. Reagents for luciferase assay 
were purchased from Promega. Further information can be found in the Life Sciences 
Reporting Summary.
Heparin-sepharose affinity chromatography
The heparin binding affinity of human full-length, histidine tagged ApoE2, ApoE3 and 
ApoE4 protein isoforms37 produced in bacteria were compared to ApoE3ch using 1 mL 
heparin columns (BioVision- 6554-1). The columns were acclimatized to room temperature 
for 1-hour prior use and washed with 5 mL of 20 mM TRIS-HCl buffer (pH 7.5). 1 mL 
sample containing 50 μg/mL of recombinant ApoE protein in 20 mM TRIS-HCl (pH7.5) 
was then recycled through the column 5 times. The column was then washed for 5 times 
using the same buffer. An increasing gradient of NaCl in 20 mM TRIS-HCl (0.025–1 M, 1 
mL per each gradient step) was passed through the column and 1 mL fractions were 
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collected and subsequently analyzed using western blotting and ELISA. We conducted n = 3 
independent experiments.
Western blotting (WB)
We used WB to detect ApoE positive fractions collected from the heparin binding columns. 
Fractions were diluted in 10 μL RIPA buffer (Cell Signaling Technology), 4 μL DTT (1 M, 
Sigma Aldrich) and 10 μl Laemmli buffer (Boston Bioproducts) to a final volume of 40 μl 
and denatured 5 min. at 60°C. Samples were separated electrophoretically for 1h at 70 V 
using 4–20% pre-cast gradient gels (Mini-PROTEAN® TGX™, Bio-Rad) and SDS-Tris-
Glycine buffer. Proteins were transferred to nitrocellulose membranes (VWR; 27376–991) 
for 1 hour at 70 V. Membranes were blocked 1 hour with Odyssey Blocking Buffer (LI-COR 
Biosciences, Lincoln, NE), and probed either 1 h room temperature (R.T.) or over-night at 
4°C with anti-his tag antibody (rb, 1:5000, Novus biologicals), and 1 hour R.T. with IRDye 
800CW donkey anti-rabbit (1:10000, LI-COR Biosciences) antibodies. Immunoreactive 
bands were visualized using the Odyssey Infrared Imaging System and visualized on the 
Image Studio version 2.1 (LI-COR Biosciences). A composite of individual gels was used to 
generate Figure 2. All western blotting reported in Figure 2 are representative of two 
independent experiments.
ELISA
Enzyme-linked immunosorbent assays (ELISA) were carried out using Ni-NTA HisSorb 
Plates (Qiagen, 35061) to measure ApoE protein isoforms (ApoE2, ApoE3, ApoE3ch and 
ApoE4) eluted from heparin columns. The fractions were diluted (1:4) in reagent diluent 
(DY008, R&D Systems) in a final volume of 200 μL. The plates were incubated for 2 hours. 
The plate was washed five times with wash buffer (DY008, R&D Systems) and incubated 
with Anti-His tag antibody (1:10,000; Novus biologicals; NBP2–61482) overnight at 4°C. 
The plate was washed five times with wash buffer (DY008) to ensure removal of unbound 
primary antibody and incubated with donkey anti-rabbit-HRP (1:10000; NA934V ECL) for 
45 minutes. The plate was then washed five times to ensure removal of secondary antibody. 
We used tetramethylbenzidine (100 μL/well; Millipore) to initiate the colorimetric reaction 
and sulfuric acid (25 μL/well; DY008 R&D Systems) to terminate the reaction after 5 
minutes incubation at room temperature and away from light. The absorbance of samples 
was then read at 450 nm using the Synergy 2 microplate reader (BioTek Instruments. Inc) 
and data processed and analyzed using Gen5 1.11 software and GraphPad Prism 
respectively. N = 3 columns per isoform in independent experiments. Representative data is 
expressed as mean ± standard error of the mean (SEM). Further information can be found in 
the Life Sciences Reporting Summary.
Generation of monoclonal antibodies against ApoE3
We generated monoclonal antibodies against a peptide including the ApoE3ch mutation: 
KLH-CTEELRVSLASHLRK-CONH2 as fee-for-service from Innovagen (Sweden). A 
cysteine residue was added at the N-terminus to facilitate conjugation of the peptides. Cell 
fusions were obtained from positive clones and cell supernatants tested for activity against 
the wild type and mutant peptides and full-length proteins using ELISA. Antibodies 
designed against the peptide were tested for their affinity to ApoE3 and ApoEch mutant 
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recombinant proteins using ELISA. The Ni-NTA HisSorb ELISA Plates (Qiagen) were used 
using the same protocol as previously described on plates coated with 0.5 μg/mL 
recombinant protein and with the variation of using Anti-ApoE (ms monoclonal; Innovagen; 
1:1,000 to 1:32,000 serial dilutions) and secondary antibody rabbit anti mouse-HRP 
(Abcam; ab97046, 1:10,000) for 45 minutes.
Antibody competition assay
A monoclonal antibody was identified as capable of detecting both the wild type and 
Christchurch mutant ApoE3 (1343A). The identify of the 1343A antibody was confirmed by 
RapidNovor (Canada) as fee-for-service. This antibody was incubated with an ApoE3 wild 
type recombinant protein (50 μg/mL in 20 mM Tris-HCl) at a 1:10 ratio and incubated for 3 
hours at room temperature. A negative control containing the cell culture supernatant media 
only, and a positive control containing the recombinant protein ApoE3 alone were used. The 
antibody/ApoE3 recombinant protein solution and controls were eluted through heparin 
columns as previously described. Fractions were collected and analyzed by ELISA and WB.
Single-cell RNA sequencing
PBMCs were isolated from fresh blood in a Ficoll gradient using standard protocols. 
Concentration and viability of cell samples were measured via hemocytometer using trypan 
blue (1:2 dilution) exclusion to identify live cells (Thermofisher Scientific, USA). Cell 
concentration ranged from 7 – 12 × 105 cells/mL with 90–95% viability. Sample single cell 
suspensions were processed using 10× Genomics’ Single Cell 3′ v3 kit according to the 
manufacturer’s instructions for a targeted recovery of 3,000 cells (10× Genomics, USA). 
Size distribution and molarity of resulting cDNA libraries were assessed via the Bioanalyzer 
High Sensitivity DNA Assay (Agilent Technologies, USA). All cDNA libraries were 
sequenced on an Illumina NextSeq 500 instrument according to Illumina and 10× Genomics 
guidelines with 1.4–1.5 pM input and 1% PhiX control library spike-in (Illumina, USA) 
generating over 40M reads per cell. Sequencing basecall data were de-multiplexed and 
aligned to the hg19 or GRCh37 human reference and transcripts identified were quantified 
using the Cell Ranger 3.0 software package with default parameters (10X Genomics, USA).
Single-cell RNA sequencing analysis
Raw sequencing data from n = 2 runs was processed using the Cell Ranger software suite 
v3.0.2 in order to perform demultiplexing, barcode processing, transcript counting and 
clustering analysis. Specifically, we generated gene-barcode matrices per each case’s 
sequencing data in MEX format, and, subsequently, we performed an aggregated analysis to 
produce an aggregated gene-barcode matrix (n = 6 cases) using the same software. The raw 
and filtered gene-barcode (cell) matrices with count data were used as input for Seurat R-
package to conduct down-stream analysis. Clustering was performed using Cell Ranger and 
viewed using Loupe Cell Browser. Cell Ranger secondary analysis and clustering analyses 
was done on both per case and aggregate data. The per case estimated number of cells 
ranged from 2,495 to 3,716 for most cases, except for JA_98 (1,179 cells), the total number 
from all cases is 16,373 cells. The mean reads per cell ranged from 43,470 to 82,240 
(Supplementary Table 2). Secondary analysis was carried out using R with Seurat R 
package38 and other R packages. The feature-barcode matrices were loaded into R using 
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Seurat to enable a wide variety of custom analyses. The gene-cell count data was normalized 
and scaled with SCTransform algorithm in Seurat R package. RunUMAP was used to 
perform non-linear dimensional reduction with the UMAP algorithm, to cluster the cells. 
Each cluster cell type was inferred by checking their marker genes expression profile against 
know gold standard single cell PBMC blood cell type labels in known PBMC dataset. The 
per case data was merged together as a whole for joint analysis in R. Further information can 
be found in the Life Sciences Reporting Summary.
Statistical analyses
All statistical analyses were conducted using GraphPad Prism 8 (GraphPad Software, La 
Jolla California USA, www.graphpad.com) and considering a p value less than 0.05 and a α 
of 0.05 as statistically significant. We used 2-way ANOVA followed by Tukey’s multiple 
comparisons test on n = 2 independent experiments (n = 3 technical replicates; F (2, 16) = 
76.05; DF = 2; ****p = 0.00000797 for 55 μM Aβ42 + ApoE3WT vs. 55 μM Aβ42 + 
ApoE3ch; ****p = 0.0000000042 for 55 μM Aβ42 vs. 55 μM Aβ42 + ApoE3WT; ***p = 
0.00022 for 55 μM Aβ42 vs. 55 μM Aβ42 + ApoE3ch) for the statistical analysis of the 
fibrillation assay (Extended Data 3a). We used the 2-tailed unpaired T-test to analyze data 
obtained by the split-luciferase Assay (n = 2 independent experiments performed with n = 3 
technical replicates; t = 2.758, DF = 1; p = 0.0202; Extended Data 3c). All representative 
data is presented as mean ± SEM (Figure 2 and Extended Data 3).
Data Availability
Anonymized clinical, genetic, and imaging data are available upon request, subject to an 
internal review by J.F.A.-V., Y.T.Q., E.M.R., and F.L. to ensure that the participants’ 
anonymity, confidentiality, and PSEN1 E280A carrier or non-carrier status are protected, 
completion of a data sharing agreement, and in accordance with University of Antioquia’s 
and Massachusetts General Hospital’s IRB and institutional guidelines. Experimental data is 
available upon request, subject to Massachusetts General Hospital and Schepens Eye 
Research Institute of Mass Eye and Ear institutional guidelines. Material requests and data 
requests will be considered based on a proposal review, completion of a material transfer 
agreement and/or a data use agreement, and in accordance with the Massachusetts General 
Hospital and Schepens Eye Research Institute of Mass Eye and Ear institutional guidelines. 
Please submit requests for participant-related clinical, genetic, and imaging data and samples 
to Y.T.Q. (yquiroz@mgh.harvard.edu) and requests for experimental data, DNA and single-
cell RNA sequencing data, and antibodies to J.F.A.-V. (joseph_arboleda@meei.harvard.edu).
Extended Data
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Fig. 1. Subject’s genealogy
Circles represent females, squares represent males, diamonds represent individuals whose 
gender has been masked for privacy, arrowhead depicts proband individual with MCI, and 
shading indicates individual with history of dementia. Deceased individuals are marked with 
a crossed bar. APOE genotypes are indicated as appropriate to preserve anonymity. Family 
links were verified by three family informants. Genotypes of relatives of the R136S 
homozygote individual were determined by Sanger sequencing (Extended Data Figure 2).
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Fig. 2. Sanger DNA sequencing of homozygous ApoEch carrier individual
Representative direct sequencing results of amplicon in APOE gene from control, proband, 
and descendants’ samples. R136 homozygous sequence is shown in upper panel from a 
control individual. In the middle panel, proband case is shown. R136S homozygous 
mutation can be observed. In bottom panel a R136S heterozygous mutation from a 
descendant is identified. Data representative of n=2 independent experiments and further 
validated independently with whole exome and whole genome sequencing.
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Fig. 3. ApoE3ch modulates Aβ aggregation
(A) Rate of Aβ42 fibril formation in the presence of C-terminus fragments of ApoE3 wild-
type (WT), APOE3ch, or in the absence of ApoE as detected by Thioflavin T fluorescence. 
Changes in relative fluorescence units (RFU) were plotted for time in minutes (min). Aβ42 
fibrillation rate was lower in the presence of ApoE3ch compared to ApoE3 WT (****p = 
0.00000797 for 55 μM Aβ42 + ApoE3WT vs. 55 μM Aβ42 + ApoE3ch; ****p = 
0.0000000042 for 55 μM Aβ42 vs. 55 μM Aβ42 + ApoE3WT; ***p = 0.00022 for 55 μM 
Aβ42 vs. 55 μM Aβ42 + ApoE3ch, 2-way ANOVA followed by Tukey’s multiple 
comparisons test; n=3 represended as mean ± SEM.). (B) Schematic representation of the 
split-luciferase complementation triggered by amyloid oligomerization in vitro. (C) 
Percentage of luminescence expressed as relative luminescence units (RLU) was obtained by 
split-luciferase complementation assay after 24 hours in culture media from 293T cells 
transfected with full-length ApoE3ch or ApoE3WT cDNA. Luciferase luminescence by 
oligomer formation is significantly reduced in ApoE3ch compared to ApoE3 WT indicating 
lower aggregation. (*p = 0.0202, 2-tailed unpaired T-test, n=6). Representative data 
presented as individual values ± SEM of n=3 independent experiments.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Brain imaging shows limited tau pathology and neurodegeneration despite high 
amyloid-β plaque burden in an individual homozygous for APOE3ch.
A, PET measurements of amyloid plaque burden (top row, PiB DVRs) and PHF tau (bottom 
row, flortaucipir standard uptake value ratios (FTP SUVRs). PET images are superimposed 
onto the medial and lateral surfaces of the left hemisphere. Color-coded scale bar indicates 
PiB DVR or FTP SUVR values; blue represents lowest binding and red represents highest 
binding, ranging from 0.8 to 2.0. The APOE3ch homozygote (left panels) had greater 
amyloid-β plaque burden and relatively limited PHF tau burden, particularly for her age, 
compared to PSEN1 E280A mutation carriers with MCI at the kindred’s typical age of 44 
years. In line with institutional review board regulations, PET imaging measurements were 
not repeated within short time intervals. B, 18F-fludeoxyglucose (FDG) PET precuneus 
cerebral metabolic rate for glucose (CMRgl) images are shown. Color-coded scale bar 
indicates FDG SUVR values; blue represents lowest values and red represents highest 
values, ranging of 0.5 to 2.1. The arrow and circle indicate that the individual homozygous 
for APOE3ch had relatively preserved CMRgl in a precuneus/posterior cingulate region 
known to be preferentially affected by Alzheimer’s disease. ChC, Christchurch. C, Brain 
imaging measurements of mean cortical amyloid plaque burden, inferior temporal cortex 
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PHF tau burden, hippocampal volume, and precuneus glucose metabolism in the PSEN1 
E280A mutation carrier with two APOE3ch alleles and exceptionally late onset of MCI (red 
dots), PSEN1 mutation carriers with MCI onset at the kindred’s typical, younger age (black 
dots) and PSEN1 mutation carriers who have not yet developed MCI (gray dots). Amyloid 
plaque burden is expressed as mean cortical-to-cerebellar distribution volume ratios (DVRs). 
Paired helical filament (PHF) tau burden is expressed as inferior temporal-to-cerebellar FTP 
SUVRs. Hippocampal volumes are expressed as hippocampal-to-whole brain volume ratios. 
Cerebral glucose metabolism is reflected as precuneus-to-whole-brain CMRgl ratios. While 
the PSEN1 E280A mutation carrier with two APOE3ch alleles had by far the highest 
amyloid plaque burden, she did not have comparably severe PHF tau burden or hippocampal 
atrophy, and she had no evidence of precuneus glucose hypometabolism.
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Figure 2. The Christchurch mutation impairs ApoE’s heparin binding.
(A, C) We used western blotting to detect ApoE in protein fractions eluted from heparin 
columns using an increasing NaCl gradient. Individual blots were cropped between 25 to 50 
kDa. Blank spaces separate individual blots that are representative of n = 2 independent 
experiments. FT = flow through. (B, D) We used ELISA to quantify differences in the NaCl 
elution pattern of different ApoE isoforms from heparin columns. N = 3 columns per 
isoform in independent experiments were analyzed side-by-side twice on different days to 
quantify differences. Error bars depict standard error of mean. In (B) ApoE2 is depicted in 
blue; ApoE3, magenta; ApoE4, black; and, ApoE3ch, cyan. In (D) wild type ApoE3 in the 
presence of an ApoE-specific antibody (1343A) is depicted in green whereas control is 
shown in magenta. ApoE3ch was eluted from the heparin column with the lowest NaCl 
concentration revealing impaired heparin binding compared to other ApoE isoforms (A, C). 
Wild type ApoE3 was also eluted with low NaCl concentrations when incubated with an 
antibody specific for an HSPG-binding domain of ApoE (B, D).
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